HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/5/E1296    most recent 00331.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Antony, N. Articles by Mitchell, M. D. Search for Related Content PubMed PubMed Citation Articles by Antony, N. Articles by Mitchell, M. D.

Myostatin regulates glucose uptake in BeWo cells

¹Liggins Institute, University of Auckland; ²National Research Centre for Growth and Development, Auckland; and ³Functional Muscle Genomics, AgResearch Limited, Ruakura Agricultural Centre, Hamilton, New Zealand

Submitted 27 May 2007 ; accepted in final form 11 August 2007

Myostatin is a member of the transforming growth factor (TGF)- superfamily, known for its ability to inhibit muscle growth. It can also regulate metabolism and glucose uptake in a number of tissues. To determine the mechanism of myostatin's effect on glucose uptake, we evaluated its actions using choriocarcinoma cell lines that are widely used as models for placental cells. Protein and mRNA were determined using immunoblotting and RT-PCR/PCR, respectively. Glucose uptake was assessed by uptake of radiolabeled deoxyglucose in vitro. All choriocarcinoma cell lines tested i.e., BeWo, JEG, and Jar, are used as models of placental cells, and all expressed myostatin protein and mRNA. Treatment of BeWo cells with myostatin resulted in inhibition of glucose uptake in a concentration-dependent manner (P < 0.01). At all concentrations tested, follistatin, a functional inhibitor of myostatin, completely blocked the inhibitory effect of myostatin (40 nM) on glucose uptake by BeWo cells (0.4 nM, P < 0.05). Follistatin treatment alone also increased glucose uptake (0.4 and 4 nM, P < 0.001; 40 nM, P < 0.05). Because BeWo cells proliferated and greater cell densities were achieved, glucose uptake declined irrespective of treatment. Myostatin treatment of BeWo cells did not alter the levels of myostatin receptor, ActRII A/B proteins. The levels of glucose transport proteins also remained unaltered in BeWo cells with myostatin treatment. This study has shown that myostatin specifically inhibits glucose uptake into BeWo cells, suggesting that locally produced myostatin may control glucose metabolism within the placenta.

myostatin; BeWo; placenta; glucose uptake; glucose transporter; glucose transporter; activin receptor; activin type II receptor A; activin type II receptor B; cell line; deoxyglucose

This article has been cited by other articles:

				D. S. Hittel, J. R. Berggren, J. Shearer, K. Boyle, and J. A. Houmard Increased Secretion and Expression of Myostatin in Skeletal Muscle From Extremely Obese Women Diabetes, January 1, 2009; 58(1): 30 - 38. [Abstract] [Full Text] [PDF]

				R. F. Cooke, J. D. Arthington, D. B. Araujo, G. C. Lamb, and A. D. Ealy Effects of supplementation frequency on performance, reproductive, and metabolic responses of Brahman-crossbred females J Anim Sci, September 1, 2008; 86(9): 2296 - 2309. [Abstract] [Full Text] [PDF]